DORVAL, QC — January 21, 2002 — After discussions with Health Canada, Novartis Pharmaceuticals Canada is alerting schizophrenia patients/guardians and physicians of emerging safety information concerning the cardiac effects of clozapine, a medication sold in Canada under the tradename Clozaril®.
Clozaril is an atypical antipsychotic medication, prescribed for patients with treatment-resistant schizophrenia. Clozaril has been available in Canada since 1991.
SOURCE: Novartis Pharmaceuticals Canada, Inc.
לכתבה המלאה הקליקו על הקישור